Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$45.00

-1.58 (-3.39%)

, TEVA

Teva

$44.56

-0.48 (-1.07%)

06:27
10/12/16
10/12
06:27
10/12/16
06:27

Neurocrine recent selloff a buying opportunity, says Leerink

Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.

NBIX

Neurocrine

$45.00

-1.58 (-3.39%)

TEVA

Teva

$44.56

-0.48 (-1.07%)

  • 06

    Nov

  • 15

    Nov

  • 14

    Dec

NBIX Neurocrine
$45.00

-1.58 (-3.39%)

06/29/16
HCWC
06/29/16
INITIATION
Target $80
HCWC
Buy
Neurocrine initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Neurocrine Biosciences with a Buy rating and $80 price target.
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
10/04/16
LEER
10/04/16
INITIATION
Target $70
LEER
Outperform
Neurocrine reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Neurocrine with an Outperform rating and $70 price target.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
TEVA Teva
$44.56

-0.48 (-1.07%)

10/05/16
WELS
10/05/16
NO CHANGE
WELS
Outperform
Teva estimates lowered on generic trends at Wells Fargo
Wells Fargo analyst David Maris lowered his estimates for Teva (TEVA) for this year and next, citing expectations for lower generic sales this year and lower margins in the generic business. Maris lowered his price target range for Teva shares to $60-$61 from $70-73 based on his lower estimates as well as the uncertainty of the environment, but keeps an Outperform rating on shares citing valuation and his belief 2017 should be a better year with several pipeline events for Teva.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.

TODAY'S FREE FLY STORIES

AOS

A.O. Smith

$54.42

1.45 (2.74%)

20:16
04/27/17
04/27
20:16
04/27/17
20:16
Downgrade
A.O. Smith rating change  »

A.O. Smith downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

FB

Facebook

$147.70

1.14 (0.78%)

20:11
04/27/17
04/27
20:11
04/27/17
20:11
Hot Stocks
Facebook improves 'Rights Manager' content protection system »

Facebook introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 08

    May

  • 16

    May

AAWW

Atlas Air

$59.80

0.4 (0.67%)

20:11
04/27/17
04/27
20:11
04/27/17
20:11
Downgrade
Atlas Air rating change  »

Atlas Air downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

UTHR

United Therapeutics

$120.50

0.51 (0.43%)

20:00
04/27/17
04/27
20:00
04/27/17
20:00
Hot Stocks
United Therapeutics announces $250M repurchase program »

United Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

CLDR

Cloudera

19:57
04/27/17
04/27
19:57
04/27/17
19:57
Syndicate
Cloudera 15M share IPO priced at $15.00, above the range »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

CYTR

CytRx

$0.68

-0.121 (-15.02%)

19:56
04/27/17
04/27
19:56
04/27/17
19:56
Hot Stocks
CytRx: Former 'SPA' for aldoxorubicin no longer applicable »

CytRx disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

EEX

Emerald Expositions Events

19:52
04/27/17
04/27
19:52
04/27/17
19:52
Syndicate
Emerald Expositions Events 15.5M share IPO priced at $17.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

GOOG

Alphabet

$874.25

2.52 (0.29%)

, GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

19:31
04/27/17
04/27
19:31
04/27/17
19:31
Hot Stocks
Google introduces development kit for Google Assistant »

Google announced in a…

GOOG

Alphabet

$874.25

2.52 (0.29%)

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:26
04/27/17
04/27
19:26
04/27/17
19:26
Hot Stocks
Sarepta: 'Productive' payer talks, ramping of patient starts continuing in Q2 »

"The number of exon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:22
04/27/17
04/27
19:22
04/27/17
19:22
Hot Stocks
Sarepta: Guidance includes only U.S. sales »

"Our guidance only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:20
04/27/17
04/27
19:20
04/27/17
19:20
Hot Stocks
Sarepta: Exondys post-market commitment data likely unavailable for couple years »

"The final protocols…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SRPT

Sarepta

$34.72

-0.14 (-0.40%)

19:18
04/27/17
04/27
19:18
04/27/17
19:18
Hot Stocks
Sarepta confirms CEO Ed Kaye to resign from role at end of current term »

Sarepta confirmed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

BSAC

Santander Chile

$23.59

-0.36 (-1.50%)

19:02
04/27/17
04/27
19:02
04/27/17
19:02
Earnings
Santander Chile reports Q1 EPS 46c, consensus 42c »

Reports Q1 ROAE up 140…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

BA

Boeing

$183.22

1.51 (0.83%)

, BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

19:01
04/27/17
04/27
19:01
04/27/17
19:01
Hot Stocks
Canada gov't objects to Boeing allegations over Bombardier pricing in U.S. »

The Government of Canada…

BA

Boeing

$183.22

1.51 (0.83%)

BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BA

Boeing

$183.22

1.51 (0.83%)

, BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

18:56
04/27/17
04/27
18:56
04/27/17
18:56
Periodicals
Boeing requests U.S. take action on Bombardier C series prices in U.S., FT says »

Boeing (BA) is aiming to…

BA

Boeing

$183.22

1.51 (0.83%)

BDRBF

Bombardier

$1.63

-0.0278 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SWN

Southwestern Energy

$7.67

-0.16 (-2.04%)

18:48
04/27/17
04/27
18:48
04/27/17
18:48
Earnings
Southwestern Energy reports Q1 adjusted EPS 18c, consensus 18c »

Reports Q1 revenue $846M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

CRMD

CorMedix

$1.04

-0.07 (-6.31%)

18:43
04/27/17
04/27
18:43
04/27/17
18:43
Syndicate
CorMedix files to sell common stock warrants, no amount given »

H.C. Wainwright & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

FET

Forum Energy

$18.10

-1.05 (-5.48%)

18:39
04/27/17
04/27
18:39
04/27/17
18:39
Earnings
Breaking Earnings news story on Forum Energy »

Forum Energy sees Q2 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

WDC

Western Digital

$85.71

1.1 (1.30%)

18:38
04/27/17
04/27
18:38
04/27/17
18:38
Hot Stocks
Western Digital: NAND supply-demand likely favorable through 'at least' 1H18 »

"Industry-wide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FET

Forum Energy

$18.10

-1.05 (-5.48%)

18:38
04/27/17
04/27
18:38
04/27/17
18:38
Earnings
Forum Energy reports Q1 adjusted EPS (14c), consensus (16c) »

Reports Q1 revenue $171M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SJR

Shaw Communications

$21.30

0.07 (0.33%)

18:36
04/27/17
04/27
18:36
04/27/17
18:36
Hot Stocks
Shaw Communications restores internet and phone services after brief outage »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTRX

Matrix Service

$16.88

-0.575 (-3.30%)

18:33
04/27/17
04/27
18:33
04/27/17
18:33
Earnings
Breaking Earnings news story on Matrix Service »

Matrix Service sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIMO

Gigamon

$36.00

-0.6 (-1.64%)

18:33
04/27/17
04/27
18:33
04/27/17
18:33
Earnings
Gigamon sees Q2 adjusted EPS 2c-7c, consensus 19c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 12

    Jun

MTRX

Matrix Service

$16.88

-0.575 (-3.30%)

18:32
04/27/17
04/27
18:32
04/27/17
18:32
Earnings
Matrix Service sees Q3 EPS (56c)-(49c), consensus 13c »

Sees Q3 revenue $250M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$85.71

1.1 (1.30%)

, TOSBF

Toshiba, also use TOSYY

$1.97

-0.01 (-0.51%)

18:31
04/27/17
04/27
18:31
04/27/17
18:31
Hot Stocks
Western Digital on Toshiba chip sale: Evaluating 'full range' of alternatives »

Western Digital (WDC)…

WDC

Western Digital

$85.71

1.1 (1.30%)

TOSBF

Toshiba, also use TOSYY

$1.97

-0.01 (-0.51%)

TOSYY

Toshiba, also use TOSBF

$11.89

0.07 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.